Post-market surveillance in the AI era

The convergence

The FDA, MHRA, Health Canada, and the EU are converging on the same expectation — that AI-enabled devices maintain continuous, documented performance monitoring in the real world.

What monitoring must cover

Performance metrics, drift detection, subgroup analyses, and adverse events. All continuously, all with documented escalation criteria.

Operationalizing it

The dashboards that satisfy regulators are the same dashboards that make the product better. Build the surveillance capability as a product surface, not a compliance chore.

The competitive angle

Companies that publish their monitoring data — even summary form — are winning enterprise trust faster than those that treat it as internal.

Two traditions merging

Device post-market surveillance and software model monitoring evolved from different regulatory traditions, one rooted in physical failure modes and adverse event reporting, the other in performance drift and retraining cycles. AI-enabled devices now sit at the intersection, and regulators are converging on an expectation that both traditions apply simultaneously rather than either one substituting for the other.

The scope regulators expect

Monitoring now needs to cover not just whether the device functions as designed, but whether its performance holds steady across the specific patient populations and clinical settings where it is actually deployed, which can diverge meaningfully from the population studied during validation. Silent performance drift in a subgroup that was underrepresented during development is exactly the failure mode this scrutiny is designed to catch.

Building the operational muscle

Few companies have the infrastructure to detect subgroup-level drift in production without deliberate investment, since it requires linking model outputs back to clinical outcomes over time, not just logging predictions. Teams that build this pipeline early treat it as a standing engineering function with a named owner, rather than a quarterly compliance exercise assembled under deadline pressure.

Turning compliance into differentiation

Hospital systems evaluating AI vendors increasingly ask to see the monitoring dashboard itself during procurement, not just a summary report, which means companies that built genuine surveillance infrastructure can use it as a sales asset rather than a cost center. This dynamic rewards the teams that invested early and penalizes those treating monitoring purely as a regulatory checkbox.

The staffing gap nobody planned for

Post-market surveillance for AI-enabled devices requires a blend of clinical, statistical, and software engineering skill that most regulatory affairs teams were never built to house, since the discipline emerged from two separate traditions merging under a single expectation. Companies are increasingly creating a distinct monitoring function rather than folding the responsibility into an existing quality team already stretched thin.

Recruiting for this hybrid skill set has proven harder than expected, and the companies that started building the team a year before it was strictly required are noticeably ahead of peers scrambling to hire under regulatory deadline pressure.

What happens when drift is caught late

A device that quietly underperforms in an underrepresented subgroup for months before detection does not just create a compliance problem, it creates a clinical trust problem that a corrective update cannot fully repair once clinicians have noticed inconsistent results firsthand. The reputational cost of late detection routinely exceeds the engineering cost of building the monitoring pipeline that would have caught it early.